India · Delayed Price · Currency is INR Zydus Lifesciences Statistics
Total Valuation
NSE:ZYDUSLIFE has a market cap or net worth of INR 1.15 trillion. The enterprise value is 1.25 trillion.
| Market Cap | 1.15T |
| Enterprise Value | 1.25T |
Important Dates
The next confirmed earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Share Statistics
NSE:ZYDUSLIFE has 997.50 million shares outstanding. The number of shares has decreased by -0.00% in one year.
| Current Share Class | 997.50M |
| Shares Outstanding | 997.50M |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 75.68% |
| Owned by Institutions (%) | 15.72% |
| Float | 240.78M |
Valuation Ratios
The trailing PE ratio is 22.98 and the forward PE ratio is 27.94. NSE:ZYDUSLIFE's PEG ratio is 13.93.
| PE Ratio | 22.98 |
| Forward PE | 27.94 |
| PS Ratio | 4.23 |
| PB Ratio | 3.88 |
| P/TBV Ratio | 11.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 54.23 |
| PEG Ratio | 13.93 |
Enterprise Valuation
| EV / Earnings | 24.76 |
| EV / Sales | 4.60 |
| EV / EBITDA | 17.11 |
| EV / EBIT | 21.08 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.27 |
| Quick Ratio | 0.67 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 1.74 |
| Debt / FCF | -9.80 |
| Interest Coverage | 15.96 |
Financial Efficiency
Return on equity (ROE) is 18.32% and return on invested capital (ROIC) is 13.47%.
| Return on Equity (ROE) | 18.32% |
| Return on Assets (ROA) | 8.13% |
| Return on Invested Capital (ROIC) | 13.47% |
| Return on Capital Employed (ROCE) | 15.87% |
| Weighted Average Cost of Capital (WACC) | 6.03% |
| Revenue Per Employee | 9.06M |
| Profits Per Employee | 1.68M |
| Employee Count | 27,917 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.57 |
Taxes
In the past 12 months, NSE:ZYDUSLIFE has paid 15.95 billion in taxes.
| Income Tax | 15.95B |
| Effective Tax Rate | 23.74% |
Stock Price Statistics
The stock price has increased by +17.83% in the last 52 weeks. The beta is 0.40, so NSE:ZYDUSLIFE's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | +17.83% |
| 50-Day Moving Average | 1,054.89 |
| 200-Day Moving Average | 962.09 |
| Relative Strength Index (RSI) | 65.75 |
| Average Volume (20 Days) | 1,448,374 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:ZYDUSLIFE had revenue of INR 271.48 billion and earned 50.40 billion in profits. Earnings per share was 50.09.
| Revenue | 271.48B |
| Gross Profit | 196.25B |
| Operating Income | 58.25B |
| Pretax Income | 67.18B |
| Net Income | 50.40B |
| EBITDA | 71.65B |
| EBIT | 58.25B |
| Earnings Per Share (EPS) | 50.09 |
Balance Sheet
The company has 49.71 billion in cash and 125.15 billion in debt, with a net cash position of -75.44 billion or -75.62 per share.
| Cash & Cash Equivalents | 49.71B |
| Total Debt | 125.15B |
| Net Cash | -75.44B |
| Net Cash Per Share | -75.62 |
| Equity (Book Value) | 295.82B |
| Book Value Per Share | 269.43 |
| Working Capital | 41.94B |
Cash Flow
In the last 12 months, operating cash flow was 21.17 billion and capital expenditures -33.94 billion, giving a free cash flow of -12.77 billion.
| Operating Cash Flow | 21.17B |
| Capital Expenditures | -33.94B |
| Depreciation & Amortization | 14.71B |
| Net Borrowing | 72.67B |
| Free Cash Flow | -12.77B |
| FCF Per Share | -12.81 |
Margins
Gross margin is 72.29%, with operating and profit margins of 21.46% and 18.56%.
| Gross Margin | 72.29% |
| Operating Margin | 21.46% |
| Pretax Margin | 24.75% |
| Profit Margin | 18.56% |
| EBITDA Margin | 26.39% |
| EBIT Margin | 21.46% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 0.09%.
| Dividend Per Share | 1.00 |
| Dividend Yield | 0.09% |
| Dividend Growth (YoY) | -90.91% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 21.95% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.09% |
| Earnings Yield | 4.39% |
| FCF Yield | -1.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for NSE:ZYDUSLIFE is 1,076.00, which is -6.67% lower than the current price. The consensus rating is "Hold".
| Price Target | 1,076.00 |
| Price Target Difference | -6.67% |
| Analyst Consensus | Hold |
| Analyst Count | 30 |
| Revenue Growth Forecast (3Y) | 10.04% |
| EPS Growth Forecast (3Y) | -1.66% |
Stock Splits
The last stock split was on October 6, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Oct 6, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
NSE:ZYDUSLIFE has an Altman Z-Score of 4.23 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.23 |
| Piotroski F-Score | 4 |